Thursday, December 18, 2025
ADVT 
International

Two pilots fall asleep as flight misses landing in Addis Ababa

Darpan News Desk IANS, 19 Aug, 2022 12:49 PM
  • Two pilots fall asleep as flight misses landing in Addis Ababa

Addis Ababa, Aug 19 (IANS) Two pilots are believed to have fallen asleep and missed their landing during a flight from Sudan to Ethiopia, media reports said.

The incident took place onboard an Ethiopian Airlines Boeing 737-800 enroute from Khartoum to Addis Ababa, according to a report by commercial aviation news site Aviation Herald, CNN reported.

Data obtained by the website indicates that the aircraft was cruising at 37,000 feet on autopilot when it failed to descend at Addis Ababa Bole International Airport, its scheduled destination, on August 15.

Air traffic control were apparently unable to reach the crew despite making several attempts at contact. However, an alarm was triggered when the plane overshot the runway and continued along the route, CNN reported.

The aircraft subsequently began to descend, landing safely around 25 minutes later.

Automatic Dependent Surveillance-Broadcast (ADS-B) data shows the aircraft overflying the runway, before beginning its descent and maneuvering for another approach.

Aviation analyst Alex Macheras has since taken to Twitter to express his shock at the "deeply concerning incident," which he suggests may have been the result of pilot exhaustion.

"Pilot fatigue is nothing new, and continues to pose one of the most significant threats to air safety -- internationally," he tweeted on Thursday.

The report comes just months after pilots at Southwest Airlines and Delta Air Lines warned airline executives that pilot exhaustion was on the rise and urged them to treat fatigue and the resulting mistakes as a safety risk.

"Fatigue, both acute and cumulative, has become Southwest Airlines' number-one safety threat," the Southwest Airlines Pilots Association, or SWAPA, told airline executives in a letter back in April, CNN reported.

MORE International ARTICLES

Extra safety scrutiny planned as virus vaccine worries grow

Extra safety scrutiny planned as virus vaccine worries grow
The poll from The Associated Press-NORC Center for Public Affairs Research found only 46% of Americans want a COVID-19 vaccine and another 29% are unsure.

Extra safety scrutiny planned as virus vaccine worries grow

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout
The COLA affects the personal finances of about 1 in 5 Americans, including Social Security recipients, disabled veterans and federal retirees, some 70 million people in all.

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout

AP-NORC poll: New angst for caregivers in time of COVID-19

AP-NORC poll: New angst for caregivers in time of COVID-19
The Associated Press-NORC Center for Public Affairs Research poll finds that 17% of Americans say they are providing ongoing caregiving, part of an informal volunteer corps.

AP-NORC poll: New angst for caregivers in time of COVID-19

Am I immune to the coronavirus if I’ve already had it?

Am I immune to the coronavirus if I’ve already had it?
Reinfection so far has been rare. The best known example: Researchers in Hong Kong said a man had mild COVID-19 and then months later was infected again but showed no symptoms.

Am I immune to the coronavirus if I’ve already had it?

Antibody drugs are no cure but seem promising for COVID-19

Antibody drugs are no cure but seem promising for COVID-19
Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines mimic an infection to spur antibody production.

Antibody drugs are no cure but seem promising for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19
Eli Lilly and Company announced the partial results Wednesday in a news release; they have not yet been published or reviewed by independent scientists.

Lilly seeks emergency use of its antibody drug for COVID-19